Cargando…

A case of tumor lysis syndrome and acute renal failure associated with elotuzumab treatment in multiple myeloma

Renal dysfunction is a common comorbidity of multiple myeloma. However, tumor lysis syndrome is a rare cause of renal dysfunction in multiple myeloma. Elotuzumab is a newly US FDA-approved monoclonal antibody used in the treatment of refractory multiple myeloma. To our knowledge, elotuzumab has not...

Descripción completa

Detalles Bibliográficos
Autores principales: Atchison, Douglas K., Humes, H. David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dustri-Verlag Dr. Karl Feistle 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5715206/
https://www.ncbi.nlm.nih.gov/pubmed/29318105
http://dx.doi.org/10.5414/CNCS109165
_version_ 1783283718597640192
author Atchison, Douglas K.
Humes, H. David
author_facet Atchison, Douglas K.
Humes, H. David
author_sort Atchison, Douglas K.
collection PubMed
description Renal dysfunction is a common comorbidity of multiple myeloma. However, tumor lysis syndrome is a rare cause of renal dysfunction in multiple myeloma. Elotuzumab is a newly US FDA-approved monoclonal antibody used in the treatment of refractory multiple myeloma. To our knowledge, elotuzumab has not been associated with a case of tumor lysis syndrome. We present the case of a patient who developed clinical tumor lysis syndrome 1 week after treatment with elotuzumab accompanied by renal failure with hyperphosphatemia, hyperkalemia, and profound hyperuricemia. His course was further complicated by significant epistaxis from the accumulation of dabigatran in acute renal failure. In spite of treatment with rasburicase and hemodiafiltration, the patient decompensated and eventually died. Risk factors for the development of tumor lysis syndrome in multiple myeloma are discussed.
format Online
Article
Text
id pubmed-5715206
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dustri-Verlag Dr. Karl Feistle
record_format MEDLINE/PubMed
spelling pubmed-57152062018-01-09 A case of tumor lysis syndrome and acute renal failure associated with elotuzumab treatment in multiple myeloma Atchison, Douglas K. Humes, H. David Clin Nephrol Case Stud Case Report Renal dysfunction is a common comorbidity of multiple myeloma. However, tumor lysis syndrome is a rare cause of renal dysfunction in multiple myeloma. Elotuzumab is a newly US FDA-approved monoclonal antibody used in the treatment of refractory multiple myeloma. To our knowledge, elotuzumab has not been associated with a case of tumor lysis syndrome. We present the case of a patient who developed clinical tumor lysis syndrome 1 week after treatment with elotuzumab accompanied by renal failure with hyperphosphatemia, hyperkalemia, and profound hyperuricemia. His course was further complicated by significant epistaxis from the accumulation of dabigatran in acute renal failure. In spite of treatment with rasburicase and hemodiafiltration, the patient decompensated and eventually died. Risk factors for the development of tumor lysis syndrome in multiple myeloma are discussed. Dustri-Verlag Dr. Karl Feistle 2017-11-22 /pmc/articles/PMC5715206/ /pubmed/29318105 http://dx.doi.org/10.5414/CNCS109165 Text en © Dustri-Verlag Dr. K. Feistle http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Atchison, Douglas K.
Humes, H. David
A case of tumor lysis syndrome and acute renal failure associated with elotuzumab treatment in multiple myeloma
title A case of tumor lysis syndrome and acute renal failure associated with elotuzumab treatment in multiple myeloma
title_full A case of tumor lysis syndrome and acute renal failure associated with elotuzumab treatment in multiple myeloma
title_fullStr A case of tumor lysis syndrome and acute renal failure associated with elotuzumab treatment in multiple myeloma
title_full_unstemmed A case of tumor lysis syndrome and acute renal failure associated with elotuzumab treatment in multiple myeloma
title_short A case of tumor lysis syndrome and acute renal failure associated with elotuzumab treatment in multiple myeloma
title_sort case of tumor lysis syndrome and acute renal failure associated with elotuzumab treatment in multiple myeloma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5715206/
https://www.ncbi.nlm.nih.gov/pubmed/29318105
http://dx.doi.org/10.5414/CNCS109165
work_keys_str_mv AT atchisondouglask acaseoftumorlysissyndromeandacuterenalfailureassociatedwithelotuzumabtreatmentinmultiplemyeloma
AT humeshdavid acaseoftumorlysissyndromeandacuterenalfailureassociatedwithelotuzumabtreatmentinmultiplemyeloma
AT atchisondouglask caseoftumorlysissyndromeandacuterenalfailureassociatedwithelotuzumabtreatmentinmultiplemyeloma
AT humeshdavid caseoftumorlysissyndromeandacuterenalfailureassociatedwithelotuzumabtreatmentinmultiplemyeloma